Login to Your Account

Biogen, Abbvie tout phase III win, expect 'dac' data to satisfy FDA

By Marie Powers
Staff Writer

Monday, June 16, 2014
Biogen Idec Inc. looked to expand its multiple sclerosis (MS) franchise with positive top-line findings from the phase III DECIDE trial of daclizumab, in joint development with partner Abbvie Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription